Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. Cessatech A/S
  6. News
  7. Summary
    CESSA   DK0061411964

CESSATECH A/S

(CESSA)
End-of-day quote NORDIC GROWTH MARKET  -  2022-12-08
1.865 DKK   +0.81%
12/07Cessatech's compensation issue in connection with the recent rights issue has been registered
AQ
11/24Cessatech's board resolves on compensation issue in connection with the recent rights issue
AQ
11/18Cessatech announces last day of trading in btu and the first day of trading in warrants of series to2
AQ
SummaryQuotesChartsNewsCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

CESSATECH'S BOARD RESOLVES ON COMPENSATION ISSUE IN CONNECTION WITH THE RECENT RIGHTS ISSUE

11/24/2022 | 11:01am EST

København, Denmark, November 24, 2022 - At a board meeting today the board of directors in Cessatech A/S ("Cessatech" or the "Company") resolved on the issue of additional units ("Compensation Units") to guarantee underwriters in the Company's recent rights issue. A total of 56,875 Compensation Units each consisting of 6 new shares and 3 warrants of series TO2 will be issued to certain investors in respect of their underwriting commitments. Cessatech's nominal share capital following the issue will increase to DKK 2,757,751 equal to 13,788,755 issued shares of DKK 0.2 each.

As described in Cessatech's offering memorandum published on October 20, 2022 in connection with the rights issue, the Company entered binding underwriting commitments with a number of investors totalling approx. DKK 13.4 million. As compensation each underwriter were offered a choice of 12% of the underwritten amount in cash or 15% in Compensation Units. The Compensation Units carry the same terms as the units in the rights issue. A number of underwriters decided to receive Compensation Units. Today the board of directors therefore resolved, based on the authorisation granted at the extraordinary general meeting held on November 4, 2022, to increase the Company's share capital with an additional 341,250 shares (corresponding to nominally DKK 68,250) and to issue 170,625 warrants of series TO2, in total corresponding to 56,875 Compensation Units consisting of 6 shares and 3 warrants of series TO2 each. Once the new issue has been registered with the Danish Business Authority (Dk: "Erhvervsstyrelsen") Cessatech's share capital will increase from nominally DKK 2,689,501 corresponding to 13,447,505 shares to nominally be DKK 2,757,751. corresponding to 13,788,755 shares.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development.

https://news.cision.com/cessatech/r/cessatech-s-board-resolves-on-compensation-issue-in-connection-with-the-recent-rights-issue,c3672658

https://mb.cision.com/Main/19921/3672658/1694330.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about CESSATECH A/S
12/07Cessatech's compensation issue in connection with the recent rights issue has been regi..
AQ
11/24Cessatech's board resolves on compensation issue in connection with the recent rights i..
AQ
11/18Cessatech announces last day of trading in btu and the first day of trading in warrants..
AQ
11/18Third quarter report Q3-2022
AQ
11/18Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/14Cessatech to Raise $2 Million in Rights Offer
MT
11/14Cessatech announces outcome of rights issue
AQ
11/08Tomorrow is the last day of the subscription period in cessatech's rights issue
AQ
11/04Minutes of the Extraordinary general meeting
AQ
10/27The subscription period has started in cessatech's rights issue
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -11,6 M -1,64 M -1,64 M
Net cash 2021 3,28 M 0,46 M 0,46 M
P/E ratio 2021 -5,44x
Yield 2021 -
Capitalization 25,7 M 3,65 M 3,65 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 2
Free-Float -
Chart CESSATECH A/S
Duration : Period :
Cessatech A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Jes Trygved Chief Executive Officer
Adam Sinding Steensberg Chairman
Bettina Nygaard Nielsen Chief Scientific Officer
Steen Henneberg Chief Medical Officer
Benedikte Bandak Head-Clinical Development & Operations